Articles from ZoomRx

BOSTON, July 23, 2026 (GLOBE NEWSWIRE) -- ZoomRx, a strategic life sciences consultancy trusted by 100+ leading biopharma companies across the world, today announced the launch of Signal-IQ: Competitive Field Intelligence, a proprietary offering from its Decision Sciences practice that gives pharma commercial teams near-real-time, NPI-level visibility into how competitor sales forces are interacting with their HCP targets. This information can be used to drive timely counter-detailing and counter-messaging with integration into CRM systems for pre-call planning and fuel dynamic recommendations. It can also be used to improve promotional evaluation, forecasting, and targeting.

Built on 15+ years of proprietary data and life sciences expertise, Sagan Agents transforms how pharma insights teams generate, access, and act on commercial intelligence, compressing customer insights workflows that traditionally take weeks into a continuous, AI-assisted loop.

Oncology brands that enter launch with below-average physician awareness are almost never able to close the gap. New data from ZoomRx “Laggards and Leaders" 2026 report shows that gap is measurable, predictable, and largely set 18 to 24 months before approval. In a market where unsuccessful launches carry lasting commercial consequences, the findings arrive at a moment when pre-launch investment decisions are under increasing scrutiny.

ZoomRx has released its latest report, “Impact of Shared Clinical Decision-Making on Pediatric Vaccine Workflows,” a dual-audience study of 50 U.S. pediatric HCPs and 50 caregivers conducted after the HHS January 5, 2026 update, which moved six vaccines (Influenza, Rotavirus, Hep A, Hep B, Meningococcal, and COVID-19) from routine recommendation to SCDM status. The central finding: the routine childhood vaccine visit may be vanishing.

CAMBRIDGE, Mass., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Global life sciences consulting firm ZoomRx is set to transform how life sciences brands monitor and evaluate TV ad campaigns with today’s launch of ZoomRx TV Tracking. ZoomRx TV Tracking combines two distinct assets – custom-built panels of verified patients and patent-pending mobile technology – to measure individual-level TV viewing behavior and ad exposure across all TV platforms. Through this distinct hyper-targeted approach, ZoomRx TV gives life sciences marketers a couch-side view of how their patients watch TV to help them prioritize ad placement and measure the in-market impact of their TV campaigns.

CAMBRIDGE, Mass., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Today, ZoomRx, a pioneering force in technological solutions for the life sciences sector, announced the launch of their latest innovation: the Ferma Engine. This groundbreaking platform serves as both an incubator and innovation hub for pharma and biotech professionals to build their own generative AI solutions.

Global life sciences consulting firm ZoomRx is set to transform the life sciences industry with today’s launch of Ferma, a groundbreaking AI-powered conversational platform specifically tailored for professionals across the pharmaceutical, biotech, and medical device industries.

CAMBRIDGE, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Global life sciences consulting firm ZoomRx is set to transform the life sciences industry with today’s launch of Ferma, a groundbreaking AI-powered conversational platform specifically tailored for professionals across the pharmaceutical, biotech, and medical device industries.  

ZoomRx is pleased to announce that multiple top 20 pharmaceutical companies have renewed their Promotional Effectiveness Tracking studies with ZoomRx. As a data-driven consulting partner for the life sciences industry, ZoomRx helps companies make better decisions by providing advanced technology via primary market research (PMR) and analytical capabilities to track the effectiveness of their promotional efforts.